Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics.
After they had been weaned off alcohol in hospital 85 severe alcoholics (above 200 g alcohol/day) were included in a double-blind study of calcium bis acetyl homotaurine (Ca AOTA, 25 mg/kg/day), a new gamma-aminobutyric acid agonist, versus placebo. Patients were treated as outpatients during the 3-month study. The only other treatment that patients received was meprobamate, 800 to 1200 mg/day, in the first month. The criterion for success was abstinence at 3 months (with normal gamma-glutamyl transpeptidase being one of the criteria). Of the 70 patients who completed the study, 33 received Ca AOTA and 37 placebo. 20 patients on Ca AOTA did not relapse, compared with 12 on placebo (p less than 0.02 by X2 test). Side-effects were noted by 7 patients on Ca AOTA and 2 on placebo. The results suggest that Ca AOTA may be useful in helping severe alcoholics who have been weaned off alcohol not to relapse.
Lhuintre
J P
JP
Daoust
M
M
Moore
N D
ND
Chretien
P
P
Saligaut
C
C
Tran
G
G
Bosimare
F
F
Hillemand
B
B
D000077443:Acamprosate; D000328:Adult; D000437:Alcoholism / Q000097:blood / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004909:Erythrocyte Indices / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011963:Receptors, GABA-A / Q000187:drug effects*; D012008:Recurrence; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D013654:Taurine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005723:gamma-Glutamyltransferase / Q000097:blood
D011963:Receptors, GABA-A; D013654:Taurine; D005723:gamma-Glutamyltransferase; D000077443:Acamprosate